Key Details
Price
$14.64Annual Revenue
$76.01 MAnnual EPS
-$1.72Annual ROE
-24.78%Beta
0.92Events Calendar
Next earnings date:
Mar 06, 2025Recent quarterly earnings:
Oct 31, 2024Recent annual earnings:
Mar 06, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
The Zymeworks story over the last two years was one of transformation and execution. Ziihera (zanidatamab) was approved in November for the treatment of second line biliary tract cancer and Zymeworks should start generating royalties on net sales this quarter. The phase 3 results for Ziihera in first-line GEA patients are now expected in Q2 2025, and represent the next critical step for Zymeworks and its partner Jazz.
Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in treatment of advanced cancers including ovarian, endometrial, and non-small cell lung cancers Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in treatment of advanced cancers including ovarian, endometrial, and non-small cell lung cancers
The PDUFA date for potential approval of Zanidatamab for the treatment of patients with 2nd-line biliary tract cancer set for November 29th of 2024. Progression-free survival data from the phase 3 HERIZON-GEA-01 study using Zanidatamab + chemotherapy plus or minus tislelizumab for treatment of patients with 1st-line GEA is expected in Q2 of 2025. Zanidatamab is being developed in collaboration with two big pharmaceutical companies, which are Jazz Pharmaceuticals and BeiGene.
VANCOUVER, British Columbia, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:
VANCOUVER, British Columbia, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced new preclinical data for Zymeworks' antibody-drug conjugate (ADC) candidates ZW220 and ZW251 in presentations at the European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR) Conference taking place in Barcelona on October 23-25, 2024.
VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the first patient has been dosed in the first-in-human Phase 1 trial (NCT06523803) to evaluate the safety and tolerability of the investigational therapy ZW171 in the treatment of advanced or metastatic ovarian cancer, NSCLC, and other MSLN-expressing cancers.
VANCOUVER, British Columbia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its third quarter 2024 financial results after market close on October 31, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on October 31, 2024 at 4:30 pm Eastern Time (ET).
ZYME's zanidatamab is under regulatory review for the treatment of second-line HER2-positive biliary tract cancer, with potential US approval in November 2024. Subsequent approval in the same indication could follow in the EU as early as Q2 '25, and in China in H2 '25. A readout from the HERIZON-GEA-01 study of zanidatamab in gastroesophageal adenocarcinoma in Q2 '25 represents a major clinical catalyst for ZYME.
Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks' proprietary antibody-drug conjugate development platforms Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks' proprietary antibody-drug conjugate development platforms
VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today reported, as required by the Nasdaq Stock Market Rule 5635(c) (the “Nasdaq Rule”), an equity inducement award to Ms. Leone Patterson, Zymeworks' Executive Vice President and Chief Business and Financial Officer.
FAQ
- What is the primary business of Zymeworks?
- What is the ticker symbol for Zymeworks?
- Does Zymeworks pay dividends?
- What sector is Zymeworks in?
- What industry is Zymeworks in?
- What country is Zymeworks based in?
- When did Zymeworks go public?
- Is Zymeworks in the S&P 500?
- Is Zymeworks in the NASDAQ 100?
- Is Zymeworks in the Dow Jones?
- When was Zymeworks's last earnings report?
- When does Zymeworks report earnings?
- Should I buy Zymeworks stock now?